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Abstract
Background: Although migraine is a disabling neurological condition that causes important disability, it remains an
area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the
unmet medical needs in migraine treated with triptans in a large Italian population.
Methods: A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was
performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the
general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4–9
triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10–14 triptan dose units per
month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was
analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan
use.
Results: Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet
medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month,
72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral
preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort,
decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM).
Conclusions: This real-life analysis underlined that the unmet medical needs concern a large part of patients
treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which
may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows
forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.
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Introduction
The World Health Organization has declared migraine
the third most common disease and the second cause of
disability [1]. It affects roughly 12–14% of the adults in
occidental countries and it is most common in the age
class 35–45 years old, with a prevalence three times
higher in women than in men [2, 3]. In Europe, the esti-
mate of migraine prevalence comes mainly from studies
based on personal interviews or questionnaires: a mean
prevalence of 14.7% has been found, with few Italian
studies included in this estimate [4]. This elevated preva-
lence is also associated with a huge economic impact,
both as direct and indirect costs: a study estimated that
for migraine the mean per-person annual costs were
€1222 with a total annual cost of €111 billion for 27
European Countries [5].
The International Classification of Headache Disorders
3rd edition defined chronic migraine (CM) as “headache
occurring on 15 or more days/month for more than
three months, which, on at least eight days/month, has
the features of migraine headache” [6]. Consequently,
episodic migraine (EM) refers to patients having head-
ache for 14 or less days per month. CM has an estimated
worldwide prevalence of 1.4% to 2.2% [7], and the rate
of EM evolving into CM is 2.5% per year [8]. In Italy,
there are scarce epidemiological data on CM: a
questionnaire-based study involving 16,577 subjects re-
ported that the prevalence of people suffering from
headache attacks for more than 15 days per month was
3.4%, despite many patients being misdiagnosed by gen-
eral practitioners [9]. Furthermore, CM is associated
with higher medical resource use and total costs com-
pared to EM, therefore the use of treatments aimed to
reduce the number of attacks could decrease the clinical
and economic burden of this disease [10].
Although migraine is a considerable clinical problem,
it remains an area of significant unmet medical needs
and of underdiagnosis and undertreatment worldwide
[11] as well as in Italy [12].
To date, pharmacological care of migraine headaches
includes acute therapies aimed to relieve the symptoms
during the attacks and preventive therapies that should
decrease the attack frequency in order to improve re-
sponsiveness to acute therapies. Beside these, several
non-pharmacological approaches, such as nutraceuticals,
behavioural techniques and acupuncture, are gaining
ground in the clinical management of migraine [13].
Acute therapy of migraine attacks consists of triptans,
ergot derivatives, and analgesics (NSAIDs) to which an
antiemetic can be added [14]. Out of these, only triptans
and ergot derivatives are specifically labelled for mi-
graine attacks treatment. Different oral drugs, originally
developed for other indications such as epilepsy, depres-
sion or high blood pressure, can be used to prevent
migraine attacks [15–17]. Finally, in 2013 the injection
of botulinum toxin A was approved as preventive ther-
apy in CM patients non-responders to oral preventive
therapies [18, 19]. Finally, recently monoclonal anti-
bodies directed against the calcitonin gene-related pep-
tide have been introduced among therapeutic strategies
for migraine with the promise to become the new fron-
tier of treatment for this disease [20, 21].
In this scenario, it has become essential to know the
real-life burden of unmet medical needs (UMN) in mi-
graine, by distinguishing between migraine with “high”
medical needs and migraine with “low” medical needs.
Another important piece of information to obtain
concerns the use of available preventive therapies and the
estimate of their effectiveness in real practice. This can be
achieved by using real-world data collected into health
administrative databases and analysed with the strategies
of the real-world evidence [22, 23].
The aim of this study was, therefore, to describe the
prevalence and characterisation of unmet medical needs
in migraine among triptan users by distinguishing be-
tween high (possible CM) and low (possible EM) needs.
Moreover, the study has provided a real-world landscape
of the use of headache preventive therapies and of an
estimate of their effectiveness in terms of reduction in
triptan use.
Methods
Data source
A real-world analysis was performed by using ReS Data-
Base (ReS DB), coming from the collaboration between
ReS (Fondazione Ricerca e Salute – Research and Health
Foundation) and CINECA (Interuniversity Consortium).
ReS DB is a patient-centred data warehouse that in-
cludes the following healthcare administrative databases
linked with each other: socio-demographic registry, re-
imbursed drug prescriptions database, hospital dis-
charges database, and outpatient services and visits
database.
ReS DB, for the period 2012–2015, collected informa-
tion of more than 12 million of Italian inhabitants resi-
dent in different Regions and Local Health Units.
Quality and usefulness of this data source is guaranteed
by several studies published in the international litera-
ture [24, 25].
Study design and patient selection
This is a longitudinal analysis of triptan-treated migraine
patients selected from a representative sample of the
general Italian population.
Patients affected by migraine were identified among
subjects aged ≥18 years and receiving at least one triptan
prescription from January 1, 2013 to December 31, 2013,
by searching in the pharmaceutical database the ATC
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(Anatomical Therapeutic Chemical) code N02CC (Select-
ive serotonin - 5HT1 agonists). The first triptan prescrip-
tion date represented the index date for each subject. The
observational periods included 24months post-index date
(follow-up period, until December 31st, 2015). Only pa-
tients with available data for the entire period (2013–
2015) were included in the analysis.
Starting from the index date, the 1-year triptan pre-
scription history was analysed to compute the monthly
average number of dose units collected by each patient.
Because the prescription database collects information
on drug dispensing and not on its actual intake, to miti-
gate possible discrepancies between these two aspects,
for each subject the sum of dose units dispensed in 1
year was divided by 12months to obtain the monthly
average number of collected dose units. This value could
be considered similar to the actual number of dose unit
intakes per patient. By taking a triptan dose unit as a
proxy of a day with migraine attack, a subject was con-
sidered affected by unmet medical needs (UMN) in mi-
graine if he/she received an average of 4 or more triptan
dose units per month in 1 year. This threshold was
established analogously to several clinical trials for mi-
graine prophylaxis setting “4 days of migraine per
month” as the lower limit for entering into the studies.
The cohort of UMN migraineurs treated with triptan,
according to the average number of triptan dose units
per month, was stratified into three groups: possible
Low-Frequency Episodic Migraine (pLF-EM; from 4 to 9
triptan dose units per month); possible High-Frequency
Episodic Migraine (pHF-EM; from 10 to 14 triptan dose
units per month); possible Chronic Migraine (pCM;
more than 14 triptan dose units per month).
Prescription patterns of preventive therapies
To describe the complete prescription pattern of
triptan-treated migraineurs, in the 12 months post-index
date the presence of prescriptions of the following oral
preventive therapies reimbursed by the Italian National
Health System (NHS) was searched: topiramate (ATC:
N03AX11), valproic acid (N03AG01), propranolol
(C07AA05), metoprolol (C07AB02), atenolol (C07AB03),
timolol (C07AA06), amitriptyline (N06AA09) and pizoti-
fen (N02CX01). Moreover, in the same period the use of
botulinum toxin was searched and identified by the pres-
ence of specific drug dispensation (ATC: M03AX01) or
by the presence of the specialist outpatient procedure of
injection (procedure code: 99.29.9 – injection of botu-
linum toxin).
Assessment of triptan use reduction
This analysis was based on the assumption that a not-
able reduction in the mean number of triptan intakes
could be a reliable proxy of migraine improvement. For
each patient the prescription history of triptans was ana-
lysed (with the same strategy described above) in two
different periods: from the index date to the 12th month
and from the 13th month to the 24th month. By
comparing these two periods, a patient was defined “im-
proved” if his/her mean number of triptan dose units
per month decreased by at least 50%.
Statistical analysis
The prevalence estimates of overall triptan users and,
among these, of UMN migraineurs (overall and for differ-
ent subgroups) were provided per 1000 adult inhabitants.
UMN migraineurs treated with triptan were described in
terms of demographic characteristics (gender and age).
Moreover, all preventive therapies (oral drugs and botu-
linum toxin injections) used in the year pre-index date
were described as rate of treated subjects, number of dif-
ferent drugs, specific active substance. Finally, the rates of
improved subjects were provided for the overall UMN
triptan-treated migraine cohort and for each subgroup.
Moreover, the improvement rates were analysed in pres-
ence and absence of oral preventive therapies or botu-
linum toxin injection. A chi-square test was performed to
compare the frequencies of improvement between sub-
jects with or without preventive therapy (oral drugs or
botulinum toxin injection). A difference was considered
statistically significant when the p value was <.01. All stat-
istical analyses were performed by Oracle SQL Developer
ver. 17.
Results
Prevalence and socio-demographic characteristics of UMN
migraineurs
Starting from a population of 12,217,384 subjects resident
in 6 Italian Regions in 2013, 10,270,683 were adults (aged
18+ years old) and, out of these, 85,048 (0.83% of adults)
received at least one prescription of triptan during 2013.
To conduct the study 82,446 triptan users with data avail-
able for the entire observational period were selected (i.e.
excluding patients who died or moved to Regions not in-
cluded in ReS DB). Therefore, the prevalence of triptan
use was of 8.0 per 1000 adult inhabitants.
Among these triptan users, 31,515 patients turned out
to be affected by UMN in migraine (i.e. with 4 or more
triptan dose units per month) with a prevalence of 3.1
per 1000 adult inhabitants. By stratifying this cohort ac-
cording to the average triptan dose units per month, 28,
263 proved affected by pEM (89.7% of UMN migrai-
neurs) and 3252 by pCM (10.3%). Among pEM patients,
22,796 (72.3% of UMN migraineurs) were affected by
pLF-EM and 5467 (17.4%) by pHF-EM. Therefore, the
prevalence estimates of different UMN triptan-treated
migraine subtypes were: 2.2 per 1000 for pLF-M, 0.5 for
pHF-EM and 0.3 for pCM (Fig. 1 and Table 1).
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Among triptan users, female gender was higher than
male (78.5% F vs. 21.5% M) and this difference was more
pronounced among UMN migraineurs treated with trip-
tan (80.9% vs. 19.1%). This gender imbalance was found
in all UMN triptan-treated migraine subtypes, although
it was slightly lower for pCM (76.2% F vs. 23.8% M).
The mean age of triptan users was 47 years old and it
was higher for those subjects affected by UMN migraine
and treated with triptan (49 years old). The mean age of
UMN triptan-treated migraineurs increased according to
the mean number of triptan dose units per month: from
48 years old for pLF-EM to 50 years old for pCM. The
distribution of subjects for the different age groups, in
all studied groups, showed a percentage increase until
the age group 40–49 years old, and a decrease in the
subsequent age groups. Finally, 5.1% of triptan users,
and 4.7% of UMN triptan-treated migraineurs, were ≥
70 years old, although triptans are not recommended in
elderly subjects (Table 1).
Preventive therapies
Out of all UMN migraineurs on triptan treatment, dur-
ing the year post-index date 21.3% received at least one
oral drug as headache preventive therapy. This percent-
age increased according to the triptan dose units re-
ceived per month: it was 18.8% among patients with
Fig. 1 Selection of unmet medical needs (UMN) in triptan-treated migraineurs among triptan users and their distribution into different migraine
subtypes according to the average triptan dose units per month
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pLF-EM, 25.2% among those with pHF-EM, and it
reached the peak of 32.8% among patients with pCM.
Patients treated with oral preventive therapy received a
single active substance, in percentages around 80% in all
different subgroups. Nevertheless, the percentage of sub-
jects with prescriptions of two or more different oral
preventive drugs increased according to the augmenta-
tion of triptan dose intake.
By analysing the specific active substances, amitriptyl-
ine was the most prescribed drug (9.4% of the cohort),
followed by topiramate (6.3%), propranolol (3.3%) and
atenolol (2.7%). The same ranking was found for all
subgroups.
The injection of botulinum toxin in the year post-
index date occurred in 0.3% of UMN triptan-treated
migraineurs; this rate increased with the augmentation
of the average triptan dose units used by patients: from
0.2% of pLF-EM to 1.0% of pCM (Table 2).
Triptan use reduction
A triptan use reduction, as proxy of migraine improve-
ment, was estimated by comparing the mean number of
triptan dose units per month in two subsequent years.
In the overall cohort of UMN migraineurs receiving trip-
tans, 22.3% of patients improved (i.e. with a ≥ 50% reduc-
tion of triptan dose units per month). The rate of
improvement decreased with the intensification of
triptan intake, ranging from 25.8% for pLF-EM to 12.0%
for pCM.
The improvement rate was significantly lower among
subjects treated with oral preventive therapies in com-
parison with those without these drugs (19.7% vs. 22.9%,
p < .01). The same analysis, performed in different sub-
groups, showed that among pLF-EM patients those
treated with oral preventive therapies had a lower fre-
quency of improvement than those not treated with
these therapies (23.7% vs 26.2%; p < .01). On the con-
trary, among pCM patients, the improvement rate of
subjects with oral preventive therapies was significantly
higher than of those not treated with these drugs (14.5%
vs. 10.9%; p < .01). Also the patients treated with botu-
linum toxin injection showed a lower improvement rate
compared to those without this treatment, however this
difference was not statistically significant among overall
UMN migraineurs (15.7% vs. 22.3%; p = .03) (Table 3).
Discussion
This study, based on real-world data collected into
healthcare administrative databases, provides the actual
burden, among triptan users, of the unmet medical
needs (UMN) in migraine in Italy, distinguishing for dif-
ferent need levels. The study reported that 8.0 per 1000
adults were on treatment with triptan, although the
Table 1 Prevalence and demographic characteristics of triptan users and unmet medical needs (UMN) in migraineurs treated with
triptans, for the overall cohort and stratified for subtypes according to the average triptan dose units per month
Overall
triptan users
Overall
UMN migraineurs
Average triptan dose units per month in 1 year
4–9 10–14 > 14
pLF-EM pHF-EM pCM
82,446 31,515 22,796 5467 3252
Rate of triptan users (%) 100 38.2 27.6 6.6 3.9
Rate of UMN migraineurs (%) – 100 72.3 17.4 10.3
Prevalence (per 1000 adult inhabitants) 8.0 3.1 2.2 0.5 0.3
Gender
Female (%) 78.5 80.9 81.5 81.0 76.2
Male (%) 21.5 19.1 18.4 19.0 23.8
Age
Mean ± SD 47 ± 13 49 ± 11 48 ± 11 49 ± 11 50 ± 11
Median 47 48 48 48 49
18–29 (%) 9.8 5.0 5.5 3.6 4.0
30–39 (%) 18.0 14.4 15.8 14.0 12.1
40–49 (%) 32.0 36.2 33.0 37.1 35.4
50–59 (%) 24.1 28.6 27.7 29.5 29.8
60–69 (%) 10.9 11.7 13.5 11.5 13.0
70–79 (%) 3.9 3.5 3.9 3.5 4.8
≥ 80 (%) 1.2 0.7 0.6 1.0 0.8
UMN Unmet medical need, pLF-EM Possible low frequency episodic migraine, pHF-EM Possible high frequency episodic migraine, pCM Possible chronic migraine
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prevalence of migraine is estimated to be 12–14% of the
general population [2, 3].
Moreover, the analysis showed that the prevalence of
UMN migraine treated with triptans was 3.1 per 1000
adults. This finding, although in the awareness that it is
lower than the estimates reported by other studies based
on different methodologies, should be evaluated in rela-
tion to the overall prevalence of triptan use. Therefore,
on the basis of this result it is possible to state that a
large part of triptan users could be considered unmet
medical need migraineurs (3.1 of 8.3 per 1000). Thus,
these findings reveal that in the group of migraineurs
receiving triptans (a therapy generally subsequent to a
correct diagnosis by neurologists) there is still a large
part of migraineurs without sufficient relief of their con-
dition. Moreover, the showed distribution of different
need levels should be taken into account to estimate the
rate of migraine sufferers who can benefit more from
new therapies.
In our study, we used the prescription of triptan as
proxy of migraine diagnosis and we adopted the average
monthly dose unit as proxy of headache attacks. A simi-
lar strategy was used by another Italian study [26] based
on electronic health records of general practitioners and
obtaining results comparable to ours. Moreover, to date,
several studies used healthcare databases to investigate
the use of triptans, both concerning Italian settings [27,
28] and other countries, such as France, the
Netherlands, Germany and Australia [29–32]. Neverthe-
less, no epidemiological data were derived from these
data sources on the real-life UMN in migraine, which
represents an important issue in the neurological field.
Although we are aware that some migraineurs could be
not treated with triptans, both due to clinical reasons
(e.g. intolerance) and to a missed treatment without rea-
sons, these drugs are specifically indicated for the acute
treatment of migraine attacks and they are reimbursed
by the Italian NHS (with routine recording into the Out-
patient Drug Prescription database). Indeed, triptan pre-
scriptions can be considered a reliable proxy of migraine
disease when administrative databases are analysed.
Additional important results of this study concern the
actual use of preventive therapies and the rate of mi-
graine improvement among triptan-treated subjects. As
a matter of fact, the oral preventive therapies and botu-
linum injection were used in a low percentage of UMN
migraineurs treated with triptans. This percentage was
low also without excluding subjects on treatment with
such drugs (e.g. beta-blockers) for a specific comorbidity
(e.g. cardiovascular disease), since the preventive effect
of a drug on headache attacks should be independent of
the presence/absence of a comorbidity. This aspect was
Table 2 Use of migraine preventive therapies (oral drugs and botulinum toxin) among triptan-treated migraineurs with unmet
medical needs (UMN) (overall cohort and stratified for the average triptan dose units per month) in the first year of follow-up
Overall
UMN migraineurs
Average triptan dose units per month in 1 year
4–9 10–14 > 14
pLF-EM pHF-EM pCM
31,515 22,2796 5467 3252
Oral Preventive Therapies in the 1st year
Treated with at least one drug (%) 21.3 18.8 25.2 32.8
1 drug (% of treated subjects) 82.9 84.9 82.0 75.7
2 drugs (% of treated subjects) 15.1 13.8 15.4 20.2
3 drugs (% of treated subjects) 1.8 1.1 2.4 3.8
4 drugs (% of treated subjects) 0.2 0,2 0,2 0,3
Active substance:
Amitriptyline (%) 9.4 8.5 11.1 13.0
Topiramate (%) 6.3 5.0 8.5 12.0
Propranolol (%) 3.3 2.8 4.1 5.3
Atenolol (%) 2.7 2.6 2.5 4.1
Valproic acid (%) 1.8 1.4 2.0 3.9
Pizotifen (%) 1.0 0.8 1.2 2.4
Metoprolol (%) 0.6 0.6 0.7 1.1
Timolol (%) 0.3 0.3 0.3 0.3
Botulinum Toxin in the 1st year
Treated (%) 0.3 0.2 0.5 1.0
UMN Unmet medical need, pLF-EM Possible low frequency episodic migraine, pHF-EM Possible high frequency episodic migraine, pCM Possible chronic migraine
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even more relevant among subjects with CM who gener-
ally suffer more from comorbidities [33]. The very low
use of all available preventive therapies could reflect a
scarce benefit of these strategies and it underlines an un-
met clinical need, especially for those subjects treated
with > 14 triptan dose units per month, which are poten-
tially affected by CM. This was confirmed by the find-
ings on migraine improvement, defined in this study as a
reduction in triptan use, which occurred only in a low
percentage of UMN migraineurs receiving triptans, with
decreasing rates as the triptan treatment intensified. The
improvement rate was lower among subjects treated
with oral preventive drugs compared with those not
treated with these drugs, especially among patients with
low need level (i.e. pLF-EM subjects). On the contrary, a
significantly higher improvement rate was observed only
among subjects with high need level (i.e. pCM patients)
treated with oral preventative drugs in comparison with
those not treated with these therapies. No significant dif-
ferences were found in improvement rates in presence
or absence of botulinum toxin injection. However, these
last results were affected by some drawbacks: the very
low number of patients receiving this treatment and the
inability to identify the actual number of attacks at the
botulinum initiation, especially among CM subjects for
whom the botulinum treatment is indicated. These
Table 3 One-year migraine improvement, in terms of modification in triptan use, among triptan-treated migraineurs with unmet
medical needs (UMN) (both overall cohort and stratified for subtypes according to the average triptan dose units per month)
Total Not Improved Improveda P
value^N N (%) N (%)
Overall UMN migraineurs (≥ 4 triptan dose units) 31,515 24,503 (77.7) 7012 (22.3)
At least one oral preventive therapy in the 1st year
Yes 6121 4913 (80.3) 1208 (19.7) <.01
No 25,394 19,590 (77.1) 5804 (22.9)
At least one botulinum toxin injection in the 1st year
Yes 191 161 (84.3) 30 (15.7) .03
No 31,324 24,342 (77.7) 6982 (22.3)
pLF-EM (4–9 triptan dose units) 22,796 16,916 (74.2) 5880 (25.8)
At least one oral preventive therapy in the 1st year
Yes 3856 2944 (76.3) 912 (23.7) <.01
No 18,940 13,972 (73.8) 4968 (26.2)
At least one botulinum toxin injection in the 1st year
Yes 71 46 (64.8) 25 (35.2) .07
No 22,725 16,870 (74.2) 5855 (25.8)
pHF-EM (10–14 triptan dose units) 5467 4725 (86.4) 742 (13.6)
At least one oral preventive therapy in the 1st year
Yes 1278 1125 (88.0) 153 (12.0) .06
No 4189 3600 (85.9) 589 (14.1)
At least one botulinum toxin injection in the 1st year
Yes 49 48 (98.0) 1 (2.0)
No 5418 4677 (86.3) 741 (13.7) .02
pCM (> 14 triptan dose units) 3252 2862 (88.0) 390 (12.0)
At least one oral preventive therapy in the 1st year
Yes 987 844 (85.5) 143 (14.5) <.01
No 2265 2018 (89.1) 247 (10.9)
At least one botulinum toxin injection in the 1st year
Yes 71 67 (94.4) 4 (5.6) .10
No 3181 2795 (87.9) 386 (12.1)
UMN Unmet medical need, pLF-EM Possible low frequency episodic migraine, pHF-EM Possible high frequency episodic migraine, pCM Possible chronic migraine
^ The differences of frequencies of migraine improvement between subjects with or without preventive therapy were tested through a chi-square test,
considering statistically significant a p value <.01
aImproved defined as reduction of ≥50% in average triptan dose units per month by comparing two subsequent years
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preliminary results point out that a large part of subjects
suffering from migraine, especially those with high med-
ical needs, to date do not receive an effective treatment,
with consequences for their health, quality of life and
economic burden for the entire system, as also argued
by previous studies [10, 12].
Strengths and limitation
The main strengths of this study were the magnitude of
the studied population and the possibility of analysing all
triptan prescriptions as the Italian NHS reimburses these
drugs. Therefore, this study was able to provide a reliable
picture of the real management of triptan-treated
migraine. On the other hand, the inability to identify the
entire population affected by migraine (i.e. patients not
treated with triptans or patients that purchased them out
of pocket), represented the main limitation of our analysis.
Although also non-treated migraineurs could be UMN
patients, this study, by using administrative data, demon-
strated that even among triptan users there was a signifi-
cant proportion of UMN patients. Another drawback
concerns the analysis of preventive therapies: in our study
we included only drugs labelled for migraine prevention
and reimbursed by the Italian NHS. This is due to the fact
that administrative databases only record reimbursed
drugs and not out-of-pocket ones. Therefore, this study
did not take into account other preventive strategies such
as not-reimbursed drugs (e.g. flunarizine), as well as non-
pharmacological treatments, such as nutraceuticals or be-
havioural techniques and acupuncture [13]. We are also
aware that in EU countries the approval of botulinum
toxin A as preventive therapy in CM patients occurred in
the first quarter of 2013, therefore our analysis, performed
on the 2013–2015 period was able to describe only the ini-
tial use of botulinum toxin for migraine.
An additional strength of this study, based on real-
world data, is the provision of the actual panorama on
drug use for migraine acute and preventive treatment.
However, this analysis was affected by the well-known
drawbacks of research studies based on administrative
databases [34], in particular, the possible discrepancy be-
tween drug dispensation and actual drug intake, or the
lack of information on precise indication and other clin-
ical features that could drive the drug choice.
Finally, concerning migraine improvement, since we
used as proxy the reduction (≥50%) in the mean number
of triptan doses, our findings should be considered as
preliminary outcomes and they should be confirmed or
rejected by future studies based on different methodolo-
gies or by integrating different types of data, as sug-
gested by other researchers [35, 36]. This also
considering that this last analysis could be affected by
misclassification since some subjects stopping the trip-
tan treatment and considered “improved” actually could
be intolerant or resistant to these drugs, which is a con-
dition involving several patients [37].
Conclusion
In conclusion, this study showed that in the Italian real
practice there is a large part of migraineurs with unmet
medical needs also among those patients treated with
triptan. This aspect should be taken into account in the
health organisation for appropriate management of mi-
graine. Indeed, not all migraine patients can attend
third-level headache centres, but some sort of “stepped
care” beginning at the primary (general practitioners)
and secondary care levels (general neurological ambula-
tories) could meet the needs of a certain portion of the
patients with UMN.
Moreover, the study underlined that the current use of
preventive therapies is scarce and with negligible bene-
fits. This could be due to the lack of effective strategies
to reduce the number of headache attacks. In view of
the new drugs being introduced for the prevention of
migraine [21], this study could represent a model to de-
sign future studies aimed to analyse appropriateness in
the management of migraine and to help policy decision
makers in the resource allocation for this disease. Fur-
thermore, the results of this study could be helpful in
the setting of critical pathways for migraine aimed to im-
prove patient outcomes and reduce the direct and indir-
ect costs of this clinical condition.
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